OUR PRODUCTS
ARIA
Qualitative Antigen Rapid Immunoassay and visual read test
ARIA ( antigen rapid immune assay ) Home use/self test that is Affordable, Accurate, accessible & backed by the most advanced digital medical platforms.
A simple Swab – DROP – wait 3 easy steps to test yourself. And, you can scan for a nurse using our teletest service ( MEDX) where an English speaking nurse ( other languages available) virtually & face to face administers the simple steps and provides interpretation of results. This is required for medical certification and in regulated markets.
The Aria is integrated with Symptoma the only Artificial intelligent digital health assistant that has been awarded a Medical device Type authorization. www.symptoma.com
Regulatory approvals include the EU , PH and many other nations.
FINA Ag
Quantitative antigen testing for initial diagnosis
COVID19 RISK PANEL (CRP)
COVID19 RISK PANEL (CRP) includes measurement of seven (7) parameters namely – Glycosylated Hemoglobin (HBA1C), Vitamin D, C-Reactive Protein, Procalcitonin, Interleukin-6, D-Dimer, & Troponin I. These parameters gives information on an individual’s immune status and predisposition to moderate to critical COVID19 complications.
nAbs (Neutralizing Antibodies)
SOFIA 2 SARS ANTIGEN FIA
Antigen testing for confirmatory diagnosis
Changing the testing game with its high mobility and affordability, the Sofia 2 boasts a sensitivity of 96.7% and a low risk of process error. Get accurate results in as fast as 15 minutes.
CAI-1
Qualitative antigen testing without the need for machines
Qualitative antigen testing without the need for machines with a sensitivity of 94.7% Sensitivity and specificity of 97.7%, the Corona Antigen Instant Test for 1 (or CAI-1) contains two antigen tests that can be detected without the use of machines, making it suitable for at-home use with the aid of a licensed medical practitioner.
AgILA
Quantitative antigen fluorescence immunoassay test
Rated at 96% sensitivity and 99% specificity, the AgILA uses a machine to detect the presence of COVID-19 antigens or proteins in subjects. Exclusive to select government agencies at the moment.
